Biocon shares rise 2% after USFDA approval for osteoporosis and bone loss drugs
Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab biosimilars, Bosaya and Aukelso. The regulator also granted provisional interchangeability for both drugs, allowing pharmacy-level substitution, which could (...)
Site référencé: The Economic Times
The Economic Times
Gold retreats from peak level to trade Rs 1,300 lower at Rs 1.13 lakh/10 g on profit booking
17/09/2025
Nifty outlook : Jefferies’ Mahesh Nandurkar sees 8–9% returns, range-bound market ahead
17/09/2025
Vedanta shares drop 4% as govt reportedly doubles down against demerger plan
17/09/2025
India’s $3.5 trillion gold holdings show it’s far from a ‘dead economy’ : Gurmeet Chadha
17/09/2025
Chris Wood of Jefferies has a warning for investors chasing AI stocks
17/09/2025
Sovereign gold bond one of dumbest government borrowing programs in world : Fundoo Professor
17/09/2025
